MENU
Showcases Stock ranks Forex

Neurocrine Bioscienc (NBIX)
104.59  0.55 (0.53%) 08-08 16:00
Open: 103.98 Pre. Close: 104.04
High: 105.98 Low: 102.93
Volume: 1,492,743 Market Cap: 10,003M
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 106.044 - 106.357 106.357 - 106.708
Low: 101.98 - 102.362 102.362 - 102.789
Close: 103.913 - 104.492 104.492 - 105.141
Stock Technical Analysis
Overall:     
Target: Six months: 123.78
One year: 144.58
Support: Support1: 97.05
Support2: 91.53
Resistance: Resistance1: 105.98
Resistance2: 123.78
Pivot: 96.22
Moving Averages: MA(5): 98.26
MA(20): 95.84
MA(100): 93.44
MA(250): 91.04
MACD: MACD(12,26): 1.17
Signal(12,26,9): 0.28
%K %D: %K(14,3): 78.15
%D(3): 57.02
RSI: RSI(14): 69.94
52-Week: High: 108.02
Low: 71.88
Change(%): 16.0
Average Vol(K): 3-Month: 727
10-Days: 794
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ NBIX ] has closed Bollinger Bands are 30.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Sun, 07 Aug 2022
IFM Investors Pty Ltd Buys 2466 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

Fri, 05 Aug 2022
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript - The Motley Fool

Thu, 04 Aug 2022
Sosei Heptares' Oral, Selective M4 Receptor Agonist - GlobeNewswire

Wed, 03 Aug 2022
Neurocrine Biosciences Q2 2022 Earnings Preview (NASDAQ:NBIX) - Seeking Alpha

Fri, 29 Jul 2022
NBIX Stock: Why Its Next Catalyst Offers A Make-Or-Break Moment - Investor's Business Daily

Sat, 23 Jul 2022
Parallel Advisors LLC Raises Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. (M) 94.87
Shares Float (M) 94.30
% Held by Insiders 1.34
% Held by Institutions 99.50
Shares Short (K) 2600
Shares Short Prior Month (K) 3730
Stock Financials
EPS 4.540
Book Value (p.s.) 14.200
Profit Margin 5.91
Operating Margin 14.86
Return on Assets (ttm) 5.6
Return on Equity (ttm) 5.5
Qtrly Rev. Growth 31.3
Gross Profit (p.s.) 8.339
Sales Per Share 12.754
EBITDA (p.s.) 2.014
Qtrly Earnings Growth -57.60
Operating Cash Flow (M) 128.70
Levered Free Cash Flow (M) 152.58
Stock Valuation
PE Ratio 23.04
PEG Ratio -17.83
Price to Book value 7.37
Price to Sales 8.20
Price to Cash Flow 77.10
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android